{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:55:15Z","timestamp":1782183315026,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06054-7","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T01:01:55Z","timestamp":1729731715000},"page":"5359-5369","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Overall survival in TP53-mutated AML and MDS"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-6859","authenticated-orcid":false,"given":"Christian J.","family":"Puzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl M.","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Rinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga K.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-3653","authenticated-orcid":false,"given":"Alexa J.","family":"Siddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"6054_CR1","doi-asserted-by":"crossref","unstructured":"Marks JA, Wang X, Fenu EM, Bagg A, Lai C (2023) TP53 in AML and MDS: the new (old) kid on the block. Blood Rev :101055","DOI":"10.1016\/j.blre.2023.101055"},{"issue":"12","key":"6054_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/gcc.21993","volume":"51","author":"A Sebaa","year":"2012","unstructured":"Sebaa A, Ades L, Baran-Marzack F et al (2012) Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 51(12):1086\u20131092","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"6054_CR3","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1080\/10428194.2016.1266625","volume":"58","author":"L Zhang","year":"2017","unstructured":"Zhang L, McGraw KL, Sallman DA, List AF (2017) The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma 58(8):1777\u20131790","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6054_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","volume":"32","author":"AM Hunter","year":"2019","unstructured":"Hunter AM, Sallman DA (2019) Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol 32(2):134\u2013144","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"6054_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135(11):791\u2013803","journal-title":"Blood"},{"issue":"12","key":"6054_CR6","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1111\/jcmm.17350","volume":"26","author":"X Li","year":"2022","unstructured":"Li X, Xu F, Wu LY, Guo J, He Q, Zhang Z (2022) Somatic mutations in SF3B1 aberrant-negative MDS-RS most commonly involved in TP53 genes. J Cell Mol Med 26(12):3586\u20133589","journal-title":"J Cell Mol Med"},{"issue":"4","key":"6054_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.clml.2021.09.013","volume":"22","author":"K Fang","year":"2022","unstructured":"Fang K, Qi J, Zhou M, Zhang Z, Han Y (2022) Clinical characteristics, prognosis, and treatment strategies of TP53 mutations in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 22(4):224\u2013235","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"6054_CR8","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/JCO.20.01659","volume":"39","author":"M Bersanelli","year":"2021","unstructured":"Bersanelli M, Travaglino E, Meggendorfer M et al (2021) Classification and personalized Prognostic Assessment on the basis of clinical and genomic features in myelodysplastic syndromes. J Clin Oncol 39(11):1223\u20131233","journal-title":"J Clin Oncol"},{"issue":"9","key":"6054_CR9","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF et al (2022) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv 6(9):2847\u20132853","journal-title":"Blood Adv"},{"issue":"10","key":"6054_CR10","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP et al (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med 26(10):1549\u20131556","journal-title":"Nat Med"},{"issue":"11","key":"6054_CR11","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","volume":"12","author":"NG Daver","year":"2022","unstructured":"Daver NG, Maiti A, Kadia TM et al (2022) TP53-Mutated myelodysplastic syndrome and Acute Myeloid Leukemia: Biology, current therapy, and future directions. Cancer Discov 12(11):2516\u20132529","journal-title":"Cancer Discov"},{"issue":"6453","key":"6054_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R et al (2019) A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365(6453):599\u2013604","journal-title":"Science"},{"issue":"18","key":"6054_CR13","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","volume":"7","author":"A Stengel","year":"2023","unstructured":"Stengel A, Meggendorfer M, Walter W et al (2023) Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv 7(18):5540\u20135548","journal-title":"Blood Adv"},{"issue":"15","key":"6054_CR14","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA et al (2022) Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 139(15):2347\u20132354","journal-title":"Blood"},{"issue":"4","key":"6054_CR15","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1002\/ajh.26845","volume":"98","author":"F Fleti","year":"2023","unstructured":"Fleti F, Chan O, Singh A et al (2023) TP53 mutations and variant allele frequency in myelodysplastic syndromes with Del(5q): a Mayo-Moffitt study of 156 informative cases. Am J Hematol 98(4):E76\u2013e79","journal-title":"Am J Hematol"},{"issue":"3","key":"6054_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C et al (2016) Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia 30(3):666\u2013673","journal-title":"Leukemia"},{"key":"6054_CR17","doi-asserted-by":"crossref","unstructured":"Yabe M, Omarbekova AZ, Hsu M et al (2021) TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers (Basel).; 13(21)","DOI":"10.3390\/cancers13215502"},{"key":"6054_CR18","doi-asserted-by":"crossref","unstructured":"Jiang Y, Gao SJ, Soubise B, Douet-Guilbert N, Liu ZL, Troadec MB (2021) TP53 in Myelodysplastic Syndromes. Cancers (Basel). ;13(21)","DOI":"10.3390\/cancers13215392"},{"issue":"1","key":"6054_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy K, Lane DP (2018) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin Oncol 15(1):13\u201330","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6054_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25(1):154\u2013160","journal-title":"Cell Death Differ"},{"issue":"1","key":"6054_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","volume":"71","author":"E Kotler","year":"2018","unstructured":"Kotler E, Shani O, Goldfeld G et al (2018) A systematic p53 mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Mol Cell 71(1):178\u2013190e178","journal-title":"Mol Cell"},{"issue":"10","key":"6054_CR22","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE et al (2018) Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet 50(10):1381\u20131387","journal-title":"Nat Genet"},{"key":"6054_CR23","doi-asserted-by":"crossref","unstructured":"Dutta S, Pregartner G, R\u00fccker FG et al (2020) Functional classification of TP53 mutations in Acute myeloid leukemia. Cancers (Basel) ;12(3)","DOI":"10.3390\/cancers12030637"},{"issue":"4","key":"6054_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00277-022-04766-2","volume":"101","author":"S Dutta","year":"2022","unstructured":"Dutta S, Moritz J, Pregartner G et al (2022) Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations. Ann Hematol 101(4):837\u2013846","journal-title":"Ann Hematol"},{"issue":"11","key":"6054_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus classification of myeloid neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"7","key":"6054_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"9","key":"6054_CR27","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","volume":"61","author":"JP Bewersdorf","year":"2020","unstructured":"Bewersdorf JP, Shallis RM, Gowda L et al (2020) Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk Lymphoma 61(9):2180\u20132190","journal-title":"Leuk Lymphoma"},{"key":"6054_CR28","doi-asserted-by":"crossref","unstructured":"Puzo CJ, Tormey CA, Rinder HM, Siddon AJ (2023) Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplant Cell Ther. ;29(7):459.e451-459.e454","DOI":"10.1016\/j.jtct.2023.04.005"},{"issue":"22","key":"6054_CR29","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H et al (2020) Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv 4(22):5681\u20135689","journal-title":"Blood Adv"},{"issue":"9","key":"6054_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125(9):1367\u20131376","journal-title":"Blood"},{"issue":"25","key":"6054_CR31","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA et al (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25):2552\u20132561","journal-title":"N Engl J Med"},{"issue":"6","key":"6054_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41389-019-0141-3","volume":"8","author":"J Smeby","year":"2019","unstructured":"Smeby J, Sveen A, Eilertsen IA et al (2019) Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis 8(6):35","journal-title":"Oncogenesis"},{"issue":"1","key":"6054_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/humu.9104","volume":"21","author":"R Holmila","year":"2003","unstructured":"Holmila R, Fouquet C, Cadranel J, Zalcman G, Soussi T (2003) Splice mutations in the p53 gene: case report and review of the literature. Hum Mutat 21(1):101\u2013102","journal-title":"Hum Mutat"},{"issue":"1","key":"6054_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41375-022-01766-z","volume":"37","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Bewersdorf JP, Hasle V et al (2023) Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia 37(1):240\u2013243","journal-title":"Leukemia"},{"issue":"6","key":"6054_CR35","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1002\/cam4.5421","volume":"12","author":"D Zhao","year":"2023","unstructured":"Zhao D, Eladl E, Zarif M et al (2023) Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency. Cancer Med 12(6):6511\u20136522","journal-title":"Cancer Med"},{"issue":"26","key":"6054_CR36","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364(26):2496\u20132506","journal-title":"N Engl J Med"},{"issue":"2","key":"6054_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3892\/etm.2020.8850","volume":"20","author":"M Yang","year":"2020","unstructured":"Yang M, Liu Q, Niu T et al (2020) Trp53 regulates platelets in bone marrow via the PI3K pathway. Exp Ther Med 20(2):1253\u20131260","journal-title":"Exp Ther Med"},{"issue":"6","key":"6054_CR38","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG et al (2017) Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 376(6):536\u2013547","journal-title":"N Engl J Med"},{"issue":"1","key":"6054_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1182\/hematology.2022000354","volume":"2022","author":"J Versluis","year":"2022","unstructured":"Versluis J, Lindsley RC (2022) Transplant for TP53-mutated MDS and AML: because we can or because we should? Hematol Am Soc Hematol Educ Program 2022(1):522\u2013527","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"17","key":"6054_CR40","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y et al (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129(17):2347\u20132358","journal-title":"Blood"},{"issue":"6","key":"6054_CR41","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.13912","volume":"172","author":"JM Middeke","year":"2016","unstructured":"Middeke JM, Herold S, R\u00fccker-Braun E et al (2016) TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 172(6):914\u2013922","journal-title":"Br J Haematol"},{"issue":"3","key":"6054_CR42","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","volume":"4","author":"G Montalban-Bravo","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Benton CB et al (2020) Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482\u2013495","journal-title":"Blood Adv"},{"issue":"1","key":"6054_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","volume":"140","author":"M Tashakori","year":"2022","unstructured":"Tashakori M, Kadia T, Loghavi S et al (2022) TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood 140(1):58\u201372","journal-title":"Blood"},{"issue":"1","key":"6054_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj W, Kewan T, Gurnari C et al (2023) Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol 16(1):91","journal-title":"J Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06054-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06054-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:11:30Z","timestamp":1735866690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06054-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6054"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06054-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Yale University Institutional Review Board policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}